Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance.
The weight loss drug maker reported second quarter sales of 78.488 billion Danish kroner, up 2% year over year (+3% at constant currency).